Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Ottawa

$25,000.00

Manufacturing encapsulated therapeutic cells and enhancing purity using a microfluidic device

FY 2014-15

Summary
The use of stem or progenitor cells in regenerative medicine applications holds the potential to revolutionizethe treatment of various diseases by restoring normal function to diseased or damages organs. NorthernTherapeutics Inc. (NTHx) is dedicated to the development of novel cell-based therapies, with current interest inpulmonary and cardiac disease. While some positive clinical successes have been demonstrated, one majorlimitation is the low cellular engraftment efficiency when using existing cell preparation and delivery methods.Recently, researchers at NTHx have developed a method for encapsulating cells in agarose microdroplets, or""cocoons"", and assessed a marked increase in cellular engraftment to target tissue, which is believed to lead toimproved treatment efficacy. However, their encapsulation protocols are highly inefficient. NTHx is inimmediate need for development of a new cell encapsulation/manufacturing method in order to increaseencapsulation efficiency, to promote cocoon monodispersity and to ensure sample purity/consistency. Theproduction of a pure monodisperse sample will allow NTHx to improve engraftment efficiencies and treatmentefficacies. NTHx expects that the engineering of an innovative microfluidic platform capable of encapsulatingcells in monodisperse hydrogel cocoons, but most importantly the development of an on-chip samplepurification protocol (removing empty cocoons, excess oil) based on dielectrophoresis, will significantlyimprove the reliability and efficiency of cell-based therapies and could become the new standard method formanufacturing cells used in regenerative medicine applications, giving NTHx a technological edge andsuperior treatment capabilities.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
468792-2014
Name nom
Godin, Michel
Department département
Physics
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Manufacturing encapsulated therapeutic cells and enhancing purity using a microfluidic device
Keyword
NSERC
Application summary
The use of stem or progenitor cells in regenerative medicine applications holds the potential to revolutionizethe treatment of various diseases by restoring normal function to diseased or damages organs. NorthernTherapeutics Inc. (NTHx) is dedicated to the development of novel cell-based therapies, with current interest inpulmonary and cardiac disease. While some positive clinical successes have been demonstrated, one majorlimitation is the low cellular engraftment efficiency when using existing cell preparation and delivery methods.Recently, researchers at NTHx have developed a method for encapsulating cells in agarose microdroplets, or""cocoons"", and assessed a marked increase in cellular engraftment to target tissue, which is believed to lead toimproved treatment efficacy. However, their encapsulation protocols are highly inefficient. NTHx is inimmediate need for development of a new cell encapsulation/manufacturing method in order to increaseencapsulation efficiency, to promote cocoon monodispersity and to ensure sample purity/consistency. Theproduction of a pure monodisperse sample will allow NTHx to improve engraftment efficiencies and treatmentefficacies. NTHx expects that the engineering of an innovative microfluidic platform capable of encapsulatingcells in monodisperse hydrogel cocoons, but most importantly the development of an on-chip samplepurification protocol (removing empty cocoons, excess oil) based on dielectrophoresis, will significantlyimprove the reliability and efficiency of cell-based therapies and could become the new standard method formanufacturing cells used in regenerative medicine applications, giving NTHx a technological edge andsuperior treatment capabilities.